Class information for:
Level 1: PHARMACOGENOMICS//PERSONALIZED MEDICINE//PROGRAM PERSONALIZED MED TARGETED THER EUT

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
10517 991 38.6 69%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
959 10268 GENETIC TESTING//JOURNAL OF GENETIC COUNSELING//GENETIC COUNSELING

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PHARMACOGENOMICS Author keyword 26 11% 23% 226
2 PERSONALIZED MEDICINE Journal 16 18% 8% 83
3 PROGRAM PERSONALIZED MED TARGETED THER EUT Address 9 59% 1% 10
4 PHARMACOGENETIC TESTING Author keyword 7 43% 1% 13
5 CANCER PHARMACOGENOMICS Author keyword 4 75% 0% 3
6 DRUG DIAGNOSTIC CODEVELOPMENT Author keyword 4 75% 0% 3
7 CLIN PHARMACOGEN CLIN SPECIMEN MANAGEMENT Address 3 100% 0% 3
8 CLINICAL UPTAKE Author keyword 3 100% 0% 3
9 PHARMACOGEN PROGRAM Address 3 100% 0% 3
10 PHARMACOGENOMICS EDUCATION Author keyword 3 100% 0% 3

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 PHARMACOGENOMICS 26 11% 23% 226 Search PHARMACOGENOMICS Search PHARMACOGENOMICS
2 PHARMACOGENETIC TESTING 7 43% 1% 13 Search PHARMACOGENETIC+TESTING Search PHARMACOGENETIC+TESTING
3 CANCER PHARMACOGENOMICS 4 75% 0% 3 Search CANCER+PHARMACOGENOMICS Search CANCER+PHARMACOGENOMICS
4 DRUG DIAGNOSTIC CODEVELOPMENT 4 75% 0% 3 Search DRUG+DIAGNOSTIC+CODEVELOPMENT Search DRUG+DIAGNOSTIC+CODEVELOPMENT
5 CLINICAL UPTAKE 3 100% 0% 3 Search CLINICAL+UPTAKE Search CLINICAL+UPTAKE
6 PHARMACOGENOMICS EDUCATION 3 100% 0% 3 Search PHARMACOGENOMICS+EDUCATION Search PHARMACOGENOMICS+EDUCATION
7 COMPANION DIAGNOSTICS 3 18% 2% 15 Search COMPANION+DIAGNOSTICS Search COMPANION+DIAGNOSTICS
8 HEALTH CARE PRIORITIZATION 2 67% 0% 2 Search HEALTH+CARE+PRIORITIZATION Search HEALTH+CARE+PRIORITIZATION
9 HEALTH ECONOMICS AND OUTCOMES RESEARCH 2 67% 0% 2 Search HEALTH+ECONOMICS+AND+OUTCOMES+RESEARCH Search HEALTH+ECONOMICS+AND+OUTCOMES+RESEARCH
10 PHARMACOTYPING 2 67% 0% 2 Search PHARMACOTYPING Search PHARMACOTYPING

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PERSONALIZED MEDICINE 19 14% 12% 123
2 EGAPP WORKING GROUP 11 40% 2% 21
3 CONSORTIUM GUIDELINES 11 78% 1% 7
4 PHARMACOGENOMICS 9 11% 8% 76
5 HLA B GENOTYPE 7 67% 1% 6
6 IMPLEMENTATION CONSORTIUM GUIDELINES 6 26% 2% 21
7 DATA SUBMISSIONS 5 63% 1% 5
8 REGULATORY DECISION MAKING 5 44% 1% 8
9 CLINICAL PHARMACOGENOMICS 4 67% 0% 4
10 PRESCRIBING INFORMATION 4 56% 1% 5

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PERSONALIZED MEDICINE 16 18% 8% 83

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Complementary versus companion diagnostics: apples and oranges? 2015 1 2 100%
Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers 2015 2 56 52%
Moving towards individualized medicine with pharmacogenomics 2004 314 18 33%
Ethical Perspectives on Translational Pharmacogenetic Research Involving Children 2015 1 23 52%
Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist 2015 2 60 22%
Measuring the value of pharmacogenomics 2005 59 35 54%
Implementing genomic medicine in the clinic: the future is here 2013 73 39 10%
An evaluation of regulatory and commercial barriers to stratified medicine development and adoption 2015 1 34 26%
A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: Challenges and implications 2008 16 20 65%
SCIENCE AND SOCIETY Challenges of translating genetic tests into clinical and public health practice 2009 46 38 32%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PROGRAM PERSONALIZED MED TARGETED THER EUT 9 59% 1.0% 10
2 CLIN PHARMACOGEN CLIN SPECIMEN MANAGEMENT 3 100% 0.3% 3
3 PHARMACOGEN PROGRAM 3 100% 0.3% 3
4 OFF CLIN PHARMACOLGENOM GRP 2 67% 0.2% 2
5 PHARMACOGENOM HUMAN GENET 2 67% 0.2% 2
6 PROGRAM PHARMACOGENOM ETH PUBL POLICY 2 67% 0.2% 2
7 PROSPECT HLTH CARE 2 67% 0.2% 2
8 REGULATORY SCI MED 2 67% 0.2% 2
9 REGULATORY SCI PUBL ADM MED 2 67% 0.2% 2
10 CLIN PHARMACOGENOM CLIN SPECIMEN MANAGEMENT 1 100% 0.2% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000186493 INTERACTION CONDITION//TARGETED CLINICAL TRIALS//INFLUENCE CONDITION
2 0.0000165156 DIRECT TO CONSUMER//PUBLIC HEALTH GENOMICS//DIRECT TO CONSUMER GENETIC TESTING
3 0.0000101776 CYP2C9//VKORC1//WARFARIN
4 0.0000090169 SULFINOSINE//OPERAT UNIT MED STAT BIOMETRY//EUROPEAN MOL GENET QUAL NETWORK
5 0.0000081708 CYP2D6//DEBRISOQUINE//CYP2C19
6 0.0000077197 ENDOXIFEN//DESMETHYLTAMOXIFEN//N DESMETHYL TAMOXIFEN
7 0.0000075032 DRUG INDUCED HYPERSENSITIVITY SYNDROME//HLA B5701//HYPERSENSITIVITY SYNDROME
8 0.0000071985 BIOBANKS//RETURN OF RESULTS//BIOBANK
9 0.0000067135 HLTH DISPAR EQU EXPOSOME//EXPOSOME//EPIDEMIOLOGIC PERSPECTIVE
10 0.0000067004 THIOPURINE METHYLTRANSFERASE//6 MERCAPTOPURINE//THIOPURINE S METHYLTRANSFERASE